Live Breaking News & Updates on Merrimack Pharmaceuticals Daily

Stay updated with breaking news from Merrimack pharmaceuticals daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Merrimack Pharmaceuticals (NASDAQ:MACK) Rating Increased to Hold at StockNews.com

Merrimack Pharmaceuticals (NASDAQ:MACK – Get Rating) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Saturday. Merrimack Pharmaceuticals Price Performance Merrimack Pharmaceuticals stock opened at $12.50 on Friday. The stock has a market cap of $178.25 million, a P/E ratio of -104.17 and […] ....

United Kingdom , United States , United Kingdom General , Eric Andersen , News Ratings For Merrimack Pharmaceuticals Daily , Merrimack Pharmaceuticals , Merrimack Pharmaceuticals Company Profile , Blackrock Inc , Securities Exchange Commission , Institutional Trading Of Merrimack Pharmaceuticals , Merrimack Pharmaceuticals Price Performance , Millennium Management , Barclays Plc , Merrimack Pharmaceuticals Inc , Get Rating , Director Eric Andersen , Exchange Commission , Merrimack Pharmaceuticals Daily , Nasdaq Mack , Stocknews Com ,

Merrimack Pharmaceuticals (NASDAQ:MACK) Upgraded to "Hold" at StockNews.com

StockNews.com upgraded shares of Merrimack Pharmaceuticals (NASDAQ:MACK – Get Rating) from a sell rating to a hold rating in a report published on Thursday morning. Merrimack Pharmaceuticals Stock Up 0.6 % Shares of NASDAQ MACK opened at $12.62 on Thursday. Merrimack Pharmaceuticals has a 12-month low of $3.00 and a 12-month high of $13.66. The […] ....

United Kingdom , United States , Eric Andersen , Merrimack Pharmaceuticals Inc , Barclays Plc , Boothbay Fund Management , Morgan Stanley , Merrimack Pharmaceuticals , Millennium Management , Hedge Funds Weigh In On Merrimack Pharmaceuticals , News Ratings For Merrimack Pharmaceuticals Daily , Merrimack Pharmaceuticals Stock , Get Rating , Director Eric Andersen , Merrimack Pharmaceuticals Daily , Nasdaq Mack , Stocknews Com ,

Merrimack Pharmaceuticals (NASDAQ:MACK) Stock Crosses Above Two Hundred Day Moving Average of $9.67

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Rating)’s stock price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $9.67 and traded as high as $12.66. Merrimack Pharmaceuticals shares last traded at $12.51, with a volume of 63,141 shares trading hands. Analysts […] ....

United Kingdom , United States , Eric Andersen , Geode Capital Management , Merrimack Pharmaceuticals , Merrimack Pharmaceuticals Trading , Securities Exchange Commission , Merrimack Pharmaceuticals Inc , News Ratings For Merrimack Pharmaceuticals Daily , Boothbay Fund Management , Insider Activity At Merrimack Pharmaceuticals , Get Rating , Director Eric Andersen , Exchange Commission , Director Noah , Capital Management , Fund Management , Two Sigma Investments , Sigma Investments , Merrimack Pharmaceuticals Daily , Nasdaq Mack ,